SCHEDULE: Divisadero Street Capital Reports Stake in Beta Bionics

Divisadero Street Capital Management, LP and affiliated entities report beneficial ownership of 6.9% of Beta Bionics, Inc. common stock.

Summary

• Divisadero Street Capital Management, LP, along with William Zolezzi, Divisadero Street Partners, L.P., Divisadero Street Partners GP, LLC, and Divisadero Street Capital, LLC, have collectively reported beneficial ownership of Beta Bionics, Inc. common stock.
• The total beneficial ownership reported is 3,072,985 shares, representing 6.9% of the class of securities.
• Divisadero Street Partners, L.P. and Divisadero Street Partners GP, LLC individually hold 2,612,985 shares, which constitutes 5.9% of the class.
• All securities reported are owned by advisory clients of Divisadero Street Capital Management, LP, with no single client other than Divisadero Street Partners, L.P. owning more than 5%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard disclosure of beneficial ownership and does not provide new operational or financial information about the company itself.

Positives

• Significant stake reported by Divisadero Street Capital Management and affiliates, indicating investor confidence or strategic interest in Beta Bionics.
• Clear disclosure of beneficial ownership and percentage of class held, providing transparency to the market.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership of securities and does not typically contain forward-looking statements or company guidance.

Management Comments

• Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment management firms to disclose significant stakes in publicly traded companies, indicating a passive investment approach or a desire to monitor a company's performance.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes in Beta Bionics.
• Investors: Provides information on a substantial holder, which may influence investment decisions.
• Management: Awareness of a significant passive investor's holdings.

Key Dates

Keywords

Beta Bionics, Divisadero Street Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing